Elsilimomab Biosimilar - Research Grade

Human

IL6

>1mg/ml

IgG1 - nd

CHO Cells

Clazakizumab Biosimilar - Research Grade (ICH5063), Siltuximab Biosimilar - Research Grade (ICH5104), Olokizumab Biosimilar - Research Grade (ICH5170), Pacibekitug Biosimilar - Research Grade (ICH5751), Sirukumab Biosimilar - Research Grade (ICH5869), Vamikibart Biosimilar - Research Grade (ICH5966), Ziltivekimab Biosimilar - Research Grade (ICH6008)

https://www.imgt.org/mAb-DB/

ICH3002

P05231

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of elsilimomab, an anti-interleukin-6 (IL-6) monoclonal antibody. It is a research-grade biosimilar built around the IL-6 target (UniProt P05231) and supplied for research use only; it is not the clinical drug and is not intended for human or veterinary use. Unlike therapeutics such as tocilizumab or siltuximab that target the IL-6 receptor or IL-6 itself in patients, this analog is intended purely for laboratory work: it reproduces the target-binding specificity of the originator so investigators can use it as a defined reagent. Typical applications include IL-6 neutralization assays, binding and epitope-characterization studies, positive and isotype controls, ADCC and antibody-drug-conjugate development workflows, and preclinical model systems. It is offered at low endotoxin levels (research grade below 1 EU/mg, with ultra-low options below 0.5 EU/mg) and can be provided in bulk milligram-to-gram quantities to support scale-up, assay standardization, and in-vivo standards. As with all biosimilar analogs here, it is unconjugated and provided for functional and comparative research rather than clinical administration. Interleukin-6 (IL-6, UniProt P05231) is a pleiotropic cytokine central to inflammation, immune regulation, and the acute-phase response. It is produced by macrophages, T cells, fibroblasts, endothelial cells, and other cell types in response to infection and tissue injury. IL-6 signals through a receptor complex comprising the ligand-binding IL-6 receptor alpha (IL-6R, CD126) and the signal-transducing subunit gp130 (IL6ST/CD130). Classic signaling uses membrane-bound IL-6R, while trans-signaling via soluble IL-6R broadens the range of responsive cells; both engage JAK/STAT3, along with SHP2/MAPK and PI3K pathways. IL-6 drives hepatic acute-phase protein production, B-cell differentiation and antibody secretion, and Th17 versus regulatory T-cell balance. Dysregulated IL-6 is implicated in rheumatoid arthritis, Castleman disease, cytokine release syndrome, and various cancers, making it a validated target for antibody-based intervention and mechanistic research.

B-cell stimulatory factor 2, BSF-2, CTL differentiation factor, CDF, Hybridoma growth factor, Interferon beta-2, IFN-beta-2, Interleukin-6, IFNB2

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Elsilimomab biosimilar available in bulk or gram quantities?

A: Yes — the Elsilimomab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Elsilimomab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Elsilimomab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Elsilimomab that binds IL6.